Company Overview
Company Type: Public Company
Website: www.telodx.com
Number of Employees: -
Ticker: TELO (TSXV)
Year Founded: 2014


Business Description
Telo Genomics Corp., a biotech company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions. It provides telomere analysis platform with diagnostic and prognostic applications; and solutions with liquid biopsies and related technologies in oncogenic and neurological diseases. The company’s lead application is Telo-MM, a solution that provides actionable information to professionals in the treatment of Multiple Myeloma, a form of blood cancer. Its solutions also include TeloView, a proprietary software platform used to quantify specific features of each patient’s telomeres. The company serves healthcare professionals, drug developers, and clinical researchers. Telo Genomics Corp. has a collaboration agreement with the Mayo Clinic to validate its Telo-MM tests for multiple myeloma. Telo Genomics Corp. was incorporated in 2014 and is headquartered in Toronto, Canada.

Financial Information (Currency: CAD, in mm) 
Market Capitalization
16.8
EBITDA
(2.6)
Total Enterprise Value
16.1
TEV/EBITDA
NM
EBIT
(2.6)
Cash & ST Invst.
0.7
P/Diluted EPS Before Extra
NM
Net Income
(2.6)
Total Debt
0.0
Price/Tang BV
18.2x
Capital Expenditure
(0.1)
Total Assets
1.0
Total Debt/EBITDA
NM




Currency in CAD in mm, LTM as of Mar-31-2023 TEV and Market Cap are calculated using a close price as of Oct-06-2023

Key Professionals
Name
Title
Weinberg, Kristan Joseph
Chief Executive Officer
Louis, Sherif 
President & CTO
Mai, Sabine 
Founder, Member of Clinical & Scientific Advisory Board and Director
Ross, Christopher 
Chief Financial Officer

Key Board Members
Name
Title
Baechler, Guido 
Independent Chairman of the Board
Mai, Sabine 
Founder, Member of Clinical & Scientific Advisory Board and Director
Bender, Richard A.
Chair of Clinical Advisory Board
Meekison, William John
Independent Director
Anderson, Kenneth C.
Member of Clinical & Scientific Advisory Board
Drachenberg, Darrel 
Member of Clinical & Scientific Advisory Board
Klotz, Laurence 
Member of Clinical & Scientific Advisory Board
Knecht, Hans 
Member of Clinical & Scientific Advisory Board
McGlennen, Ronald C.
Independent Director
Rogers, Hugh A. D.
Independent Director


Primary Industry Classification
Biotechnology


Primary Office Location
MaRS Centre South Tower Suite 200 101 College Street | Toronto, ON | M5G 1L7 | Canada

Current and Pending Investors
Knight Therapeutics Inc. (TSX:GUD), ScreenCell SA

Prior Investors
AlphaNorth Asset Management

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.24
Market Cap (mm)
16.8
Open
 0.23
Shares Out. (mm)
71.3
Previous Close
 0.24
Float %
92.4%
Change on Day
0.00
Shares Sold Short (mm)
-
Change % on Day
0.0%
Dividend Yield %
-
Day High/Low
 0.24/ 0.21
Diluted EPS Excl. Extra Items
(0.04)
52 wk High/Low
 0.45/ 0.21
P/Diluted EPS Before Extra
NM
Volume (mm)
0.03
Avg 3M Dly Vlm (mm)
0.02
Beta 5Y
1.85


 
Delayed Quote** | Last Updated on Oct-06-2023 12:00 AM (GMT-5)
TSXV:TELO - Common Stock


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Plicit Capital Corp.
As of September 8, 2016, Plicit Capital Corp. was acquired by 3D Signatures Inc., in a reverse merger transaction. Plicit Capital Corp. does not have significant operations. It intends to identify and evaluate assets, properties, or businesses with a view to acquisition or participation by completing a qualifying transaction. The company was incorporated in 2011 and is headquartered in Calgary, Canada.

United States and Canada
Asset Management and Custody Banks
-
0.00
0.00


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
May-19-2023
Jun-14-2023
Private Placement
Target
Telo Genomics Corp. (TSXV:TELO)


2.13
Jun-18-2021
Jul-05-2021
Private Placement
Target
Telo Genomics Corp. (TSXV:TELO)


1.85
Oct-11-2019
Nov-25-2019
Private Placement
Target
Telo Genomics Corp. (TSXV:TELO)


1.30
Nov-27-2017
Dec-05-2017
Private Placement
Target
3D Signatures Inc. (nka:Telo Genomics Corp. (TSXV:TELO))


1.28
Oct-25-2017
Cancelled
Private Placement
Target
3D Signatures Inc. (nka:Telo Genomics Corp. (TSXV:TELO))


1.96
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Aug-29-2023
Product-Related Announcements
Telo Genomics Corp. Reports Substantial Progress Toward Clinical Launch of Teloview-SMM
Jun-14-2023
Private Placements
Telo Genomics Corp. announced that it has received CAD 2.833875 million in funding
Jun-12-2023
Product-Related Announcements
Telo Genomics Corp. Presents Positive Data in Newly Diagnosed Multiple Myeloma Drug Resistance Study at EHA 2023
Jun-05-2023
Product-Related Announcements
Telo Genomics Corp. Presents Superior Results of Its Smoldering Multiple Myeloma Studies At Asco 2023
May-19-2023
Private Placements
Telo Genomics Corp. announced that it expects to receive CAD 2 million in funding


Advisors
Most Recent Auditor
Smythe LLP
Private Placement Advisors
Canaccord Genuity Corp., CIBC World Markets, Inc., Haywood Securities Inc., Industrial Alliance Securities Inc., Leede Jones Gable Inc., PI Financial Corp., RBC Dominion Securities Inc., Research Capital Corporation, Troutman Pepper Hamilton Sanders LLP
Public Offering Advisors
Blake, Cassels & Graydon LLP, MNP LLP


Most Recent Auditor
Smythe Ratcliffe


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
S&P Global Compustat

Oct 05, 2023 04:01 AM
TELO
Telo Genomics Corp 2023_10_05
Reports
14
GlobalData

Sep 15, 2023 10:10 AM
TELO
Telo Genomics Corp (TELO.CVE) - Medical Devices Product Pipeline Summary
Reports
42
MarketLine

Sep 14, 2023 06:01 AM
TELO
3D Signatures Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
Reports
119
GlobalData

Sep 13, 2023 02:02 AM
TELO
Telo Genomics Corp (TELO.CVE) - Financial Analysis Review
Reports
89
S&P Global Compustat

Sep 07, 2023 04:05 AM
TELO
Telo Genomics Corp 2023_09_07
Reports
14
GlobalData

Aug 29, 2023 01:46 AM
TELO
Telo Genomics Corp (TELO.CVE) - Medical Equipment - Deals and Alliances Profile
Reports
27
S&P Global Compustat

Jul 06, 2023 03:28 AM
TELO
Telo Genomics Corp 2023_07_06
Reports
14
GlobalData

Jun 13, 2023 10:27 PM
TELO
Telo Genomics Corp (TELO.CVE) - Financial Analysis Review
Reports
88
GlobalData

Jun 09, 2023 09:10 AM
TELO
Telo Genomics Corp (TELO.CVE) - Medical Devices Product Pipeline Summary
Reports
42
S&P Global Compustat

Jun 01, 2023 04:24 AM
TELO
Telo Genomics Corp 2023_06_01
Reports
14


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Mai Ph.D., Sabine 

2,810,433

3.94

0.7

Oct-24-2022


Louis MSc, Ph.D., PMP, Sherif 

1,450,000

2.03

0.3

Dec-30-2022


Rogers B.Sc., LL.B, Hugh A. D.

1,062,471

1.49

0.2

Oct-24-2022


CATAM Asset Management AG

100,000

0.14

0.0

Jun-30-2023


Weinberg, Kristan Joseph

80,000

0.11

0.0

Mar-07-2023


Meekison BA, C.M.A., CPA, CIM, CMA, CPA, P.Log, William John

30,000

0.04

0.0

Oct-24-2022



 


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Telo-HL (Future), Telo-LC (Future), Telo-MM (Future), Telo-PC (Future), TeloView (Future), TeloView Score (Future)


Upcoming Events
Date/Time
Type
Oct-11-2023
Estimated Earnings Release Date (S&P Global Derived)
Nov-30-2023
Annual General Meeting
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Company Name
Source
Form Type
Size
Sep-25-2023
Telo Genomics Corp. (TSXV:TELO)
SEDAR
Notice of the Meeting and Record Date
313 KB
Sep-25-2023
Telo Genomics Corp. (TSXV:TELO)
SEDAR
Notice of the Meeting and Record Date
313 KB
Sep-25-2023
Telo Genomics Corp. (TSXV:TELO)
SEDAR
Notice of the Meeting and Record Date
313 KB
Sep-07-2023
Telo Genomics Corp. (TSXV:TELO)
SEDAR
News Releases
199 KB
Aug-29-2023
Telo Genomics Corp. (TSXV:TELO)
SEDAR
News Releases
235 KB
Jun-30-2023
Telo Genomics Corp. (TSXV:TELO)
SEDAR
News Releases
47 KB
Jun-22-2023
Telo Genomics Corp. (TSXV:TELO)
SEDAR
Material Change Report
147 KB
Jun-14-2023
Telo Genomics Corp. (TSXV:TELO)
SEDAR
News Releases
50 KB
Jun-12-2023
Telo Genomics Corp. (TSXV:TELO)
SEDAR
News Releases
44 KB
Jun-06-2023
Telo Genomics Corp. (TSXV:TELO)
SEDAR
News Releases
51 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Weinberg, Kristan Joseph (Chief Executive Officer)
Mar-07-2023
Common Shares
80,000
23,805
Open Market Acquisition
New
Multiple
Louis MSc, Ph.D., PMP, Sherif  (President & CTO)
Dec-30-2022
Common Shares
400,000
60,409
Derivative Exercise and Retained Stock
38.10
Multiple
Rogers B.Sc., LL.B, Hugh A. D. (Independent Director)
Oct-29-2021
Common Shares
274,510
60,340
Derivative Exercise and Retained Stock
34.84
Multiple
Meekison BA, C.M.A., CPA, CIM, CMA, CPA, P.Log, William John (Independent Director)
Jul-02-2021
Common Shares
10,000
5,517
Private Acquisition
50.00
Exchange Announcement
Cheung B.Com., CA, CPA, Ryan E. S. K. (Former Director)
Mar-25-2021
Common Shares
50,000
8,107
Private Acquisition
11.11
Exchange Announcement
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Baechler, Guido 
Independent Chairman of the Board
-
-
Guido.baechler@mainz-biomed.com
Mai, Sabine 
Founder, Member of Clinical & Scientific Advisory Board and Director
-
-

Bender, Richard A.
Chair of Clinical Advisory Board
-
-

Meekison, William John
Independent Director
(604) 649-8778
-
wjmeekison@gmail.com
Anderson, Kenneth C.
Member of Clinical & Scientific Advisory Board
-
-

Drachenberg, Darrel 
Member of Clinical & Scientific Advisory Board
-
-

Klotz, Laurence 
Member of Clinical & Scientific Advisory Board
-
-

Knecht, Hans 
Member of Clinical & Scientific Advisory Board
-
-

McGlennen, Ronald C.
Independent Director
-
-

Rogers, Hugh A. D.
Independent Director
(604).650.6162
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Weinberg, Kristan Joseph
Chief Executive Officer
-
-

Louis, Sherif 
President & CTO
-
-
sherif.louis@telodx.com
Mai, Sabine 
Founder, Member of Clinical & Scientific Advisory Board and Director
-
-

Ross, Christopher 
Chief Financial Officer
-
-

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
